 Odonate is a small biotech attempting to win approval for Tesetaxel, a chemotherapy treatment indicated for treatment of HER2 negative metastatic breast cancer. The companys share price nose dived from 45 in June to 13 in September last year after management released results from a registrational Phase 3 trial of Tesetaxel. 